Sector: Consumer Non-Cyclicals | Industry: Food Processing |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 21 E. Long Lake Road, Suite 100 BLOOMFIELD HILLS MI 48304 |
Tel: | 1-212-2016614 |
Website: | https://zivobioscience.com |
IR: | See website |
Key People | ||
John B. Payne Chairman of the Board, President, Chief Executive Office, Director | Keith R. Marchiando Chief Financial Officer |
Business Overview |
Zivo Bioscience, Inc. is a research and development company. The Company operates in both the biotech and agtech sectors, with an intellectual property portfolio comprised of algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health. Its product candidates are at different stages of development for different applications. It is developing a product candidate targeting poultry gut health. It is developing products for Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Algal biomass for human consumption, and Biomass for supporting skin health/anti-aging. It is focused on licensing and selling natural bioactive ingredients derived from their proprietary algae cultures to animal, human and dietary supplement, and medical food manufacturers. |
Financial Overview |
For the fiscal year ended 31 December 2023, Zivo Bioscience Inc revenues increased from $0K to $28K. Net loss decreased 11% to $7.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and Development decrease of 39% to $1.4M (expense), General and Administrative decrease of 9% to $5.9M (expense). |
Employees: | 8 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $19.13M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.03M as of Dec 31, 2023 |
EBITDA (TTM): | -$7.26M as of Dec 31, 2023 |
Net annual income (TTM): | -$7.78M as of Dec 31, 2023 |
Free cash flow (TTM): | -$5.80M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 2,777,639 as of Mar 12, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |